2022 Fiscal Year Final Research Report
LYSOPHOSPHATIDYLSERINE MAY BE INVOLVED IN LIVER FIBROSIS
| Project/Area Number |
21K15659
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 52010:General internal medicine-related
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2021-04-01 – 2023-03-31
|
| Keywords | リゾリン脂質 / リゾホスファチジルセリン / 肝線維化 |
|---|
| Outline of Final Research Achievements |
Lysophospholipids (LPLs), such as lysophosphatidic acid and sphingosine 1-phosphate are attracting attention as second-generation lipid mediators. Lysophosphatidylserine (LysoPS), a phosphatidylserine-derived LPL, has recently been identified as a specific receptor, such as GPR34 and GPR174, P2Y10, and has begun to attract attention as a novel lipid mediator.
In this study, it was suggested that LysoPS is involved in liver fibrosis in vitro. In vivo study, upregulation of LysoPS receptor was observed in hepatic myofibroblast-like stellate cells, suggesting that LysoPS may also be involved in liver fibrosis. Furthermore, an increase in LysoPS of some fatty acid molecular species was observed in mouse plasma, suggesting the possibility of laboratory medical application of LysoPS as a marker of liver fibrosis.
|
| Free Research Field |
消化器内科学
|
| Academic Significance and Societal Importance of the Research Achievements |
培養細胞を用いた検討にて，LysoPSは肝臓の線維形成に関与していると推察された.またヒト検体では肝星細胞においてLysoPS受容体の発現亢進が認められ,LysoPSは肝線維化にも関与している可能性が示唆された.さらにマウス血漿において一部の脂肪酸分子種のLysoPSの上昇を認め,LysoPSの肝線維化マーカーとしての検査医学的応用の可能性が示唆された.今後受容体アンタゴニストによる肝線維化の治療法の開発，アゴニストによる癌進展抑制剤の開発などが期待される.
|
